BioDlink International Company Limited (1875), Wuxi Biologics, and the Offeror Issue Clarification on Share Options Under Rule 3.8

Bulletin Express

03/03

BioDlink International Company Limited (1875), the Offeror, and Wuxi Biologics jointly referenced their previous announcements dated 14 January 2026, 12 February 2026, and 1 March 2026 regarding the Offers and related matters under the Takeovers Code. According to the announcement, after the vesting of 0.14 million Share Options on 1 March 2026, there are 7.63 million outstanding Share Options in total, comprising 7.49 million vested unexercised options and 0.14 million unvested options.

The clarification indicates that all other information and content presented in the 1 March 2026 announcement remain unchanged. The company reiterates that the clarification is supplemental and should be read alongside the previously issued announcement pursuant to Rule 3.8 of the Takeovers Code.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1144819988"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1144819988\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1144819988?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-03 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144819988","market":"hk","top_or_hot":-1,"title":"BioDlink International Company Limited (1875), Wuxi Biologics, and the Offeror Issue Clarification on Share Options Under Rule 3.8","media":"Bulletin Express","content":"<p>BioDlink International Company Limited (1875), the Offeror, and Wuxi Biologics jointly referenced their previous announcements dated 14 January 2026, 12 February 2026, and 1 March 2026 regarding the Offers and related matters under the Takeovers Code. According to the announcement, after the vesting of 0.14 million Share Options on 1 March 2026, there are 7.63 million outstanding Share Options in total, comprising 7.49 million vested unexercised options and 0.14 million unvested options.</p>\n<p>The clarification indicates that all other information and content presented in the 1 March 2026 announcement remain unchanged. The company reiterates that the clarification is supplemental and should be read alongside the previously issued announcement pursuant to Rule 3.8 of the Takeovers Code.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioDlink International Company Limited (1875), Wuxi Biologics, and the Offeror Issue Clarification on Share Options Under Rule 3.8</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioDlink International Company Limited (1875), Wuxi Biologics, and the Offeror Issue Clarification on Share Options Under Rule 3.8\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-03 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioDlink International Company Limited (1875), the Offeror, and Wuxi Biologics jointly referenced their previous announcements dated 14 January 2026, 12 February 2026, and 1 March 2026 regarding the Offers and related matters under the Takeovers Code. According to the announcement, after the vesting of 0.14 million Share Options on 1 March 2026, there are 7.63 million outstanding Share Options in total, comprising 7.49 million vested unexercised options and 0.14 million unvested options.</p>\n<p>The clarification indicates that all other information and content presented in the 1 March 2026 announcement remain unchanged. The company reiterates that the clarification is supplemental and should be read alongside the previously issued announcement pursuant to Rule 3.8 of the Takeovers Code.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01875","symbol_name":"东曜药业-B","start_time":0,"source_url":"","article_id":"1144819988","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144819988","pubTimestamp":1772539511,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"BioDlink International Company Limited (1875), the Offeror, and Wuxi Biologics jointly referenced their previous announcements dated 14 January 2026, 12 February 2026, and 1 March 2026 regarding the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01875":"东曜药业-B"},"translate_title":"BioDlink International Company Limited(1875)、药明生物及要约人根据第3.8条就购股权作出澄清","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01875":1},"content_text":"BioDlink International Company Limited (1875), the Offeror, and Wuxi Biologics jointly referenced their previous announcements dated 14 January 2026, 12 February 2026, and 1 March 2026 regarding the Offers and related matters under the Takeovers Code. According to the announcement, after the vesting of 0.14 million Share Options on 1 March 2026, there are 7.63 million outstanding Share Options in total, comprising 7.49 million vested unexercised options and 0.14 million unvested options.\nThe clarification indicates that all other information and content presented in the 1 March 2026 announcement remain unchanged. The company reiterates that the clarification is supplemental and should be read alongside the previously issued announcement pursuant to Rule 3.8 of the Takeovers Code.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}